Lisanti Capital Growth LLC Sells 15,495 Shares of GeneDx Holdings Corp. $WGS

Lisanti Capital Growth LLC lessened its stake in GeneDx Holdings Corp. (NASDAQ:WGS) by 27.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 41,128 shares of the company’s stock after selling 15,495 shares during the quarter. GeneDx makes up about 1.3% of Lisanti Capital Growth LLC’s holdings, making the stock its 27th largest position. Lisanti Capital Growth LLC owned approximately 0.14% of GeneDx worth $5,349,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. ARK Investment Management LLC bought a new stake in GeneDx during the third quarter worth $48,157,000. Franklin Resources Inc. lifted its holdings in GeneDx by 101.9% during the third quarter. Franklin Resources Inc. now owns 681,381 shares of the company’s stock worth $73,412,000 after acquiring an additional 343,954 shares during the period. Amova Asset Management Americas Inc. bought a new stake in GeneDx during the third quarter worth $31,444,000. Assenagon Asset Management S.A. lifted its holdings in GeneDx by 1,358.7% during the fourth quarter. Assenagon Asset Management S.A. now owns 205,895 shares of the company’s stock worth $26,779,000 after acquiring an additional 191,780 shares during the period. Finally, Invesco Ltd. lifted its holdings in GeneDx by 42.3% during the second quarter. Invesco Ltd. now owns 554,419 shares of the company’s stock worth $51,178,000 after acquiring an additional 164,840 shares during the period. Institutional investors own 61.72% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Craig Hallum reiterated a “buy” rating and set a $85.00 price target on shares of GeneDx in a report on Tuesday, May 5th. Wall Street Zen lowered GeneDx from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Weiss Ratings upgraded GeneDx from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 15th. Guggenheim dropped their price target on GeneDx from $100.00 to $70.00 and set a “buy” rating on the stock in a report on Tuesday, May 5th. Finally, Wells Fargo & Company reiterated an “overweight” rating and set a $75.00 price target (down from $155.00) on shares of GeneDx in a report on Tuesday, May 5th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $96.43.

Insider Buying and Selling at GeneDx

In related news, Director Keith A. Meister purchased 46,273 shares of GeneDx stock in a transaction dated Friday, May 15th. The stock was bought at an average cost of $38.91 per share, for a total transaction of $1,800,482.43. Following the completion of the transaction, the director owned 4,784,570 shares in the company, valued at $186,167,618.70. This trade represents a 0.98% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Kevin Feeley sold 392 shares of GeneDx stock in a transaction on Wednesday, April 29th. The shares were sold at an average price of $65.19, for a total value of $25,554.48. Following the completion of the transaction, the chief financial officer owned 34,942 shares of the company’s stock, valued at approximately $2,277,868.98. This trade represents a 1.11% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have bought 2,225,941 shares of company stock worth $95,494,951 and have sold 104,028 shares worth $7,377,165. Corporate insiders own 29.60% of the company’s stock.

GeneDx Stock Performance

Shares of WGS opened at $47.31 on Friday. The firm has a market cap of $1.40 billion, a PE ratio of -17.65 and a beta of 2.06. The stock’s fifty day moving average price is $59.72 and its two-hundred day moving average price is $98.90. The company has a debt-to-equity ratio of 0.38, a current ratio of 3.09 and a quick ratio of 2.95. GeneDx Holdings Corp. has a 1 year low of $32.21 and a 1 year high of $170.87.

GeneDx (NASDAQ:WGS) last issued its earnings results on Monday, May 4th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.22). The firm had revenue of $102.25 million during the quarter, compared to the consensus estimate of $112.46 million. GeneDx had a negative net margin of 17.58% and a positive return on equity of 9.15%. During the same quarter in the previous year, the firm earned ($0.23) earnings per share. On average, equities research analysts forecast that GeneDx Holdings Corp. will post -1 EPS for the current year.

GeneDx Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.